Back to top
more

Thermo Fisher Scientific (TMO)

(Real Time Quote from BATS)

$609.85 USD

609.85
561,188

+11.82 (1.98%)

Updated Aug 6, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Medtronic Publishes IN.PACT AV Access Trial Study Results

by Zacks Equity Research

Medtronic's (MDT) IN.PACT AV demonstrates significant reductions in hospital visits for AV fistulae maintenance, which is leading to successful and uninterrupted dialysis of ESRD patients.

Globus Medical Sees Strong Rebound Despite Coronavirus Crisis

by Zacks Equity Research

Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.

Allscripts' Collaboration to Advance Healthcare Innovation

by Zacks Equity Research

Allscripts (MDRX) partners with Israel's Sheba Medical Center to help enhance healthcare innovation with smarter technology, thereby improving patient outcomes.

QIAGEN Launches Primer Panel for NGS of Coronavirus Genome

by Zacks Equity Research

QIAGEN (QGEN) expands the NGS portfolio with the launch of the genome analyzing panel to support holistic research of the SARS-CoV-2.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.

Ecolab's Synergex Sanitizer & Disinfectant Gets First EPA Nod

by Zacks Equity Research

Ecolab's (ECL) Synergex Santizer & Disinfectant becomes the first product to receive U.S. EPA for efficacy against biofilms.

Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking

by Zacks Equity Research

Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.

Urmimala Biswas headshot

Will Thermo Fisher's (TMO) Failed QIAGEN Deal Cost it a Lot?

by Urmimala Biswas

The COVID-19 tailwinds are significantly stronger than what Thermo Fisher (TMO) had originally expected in March.

McKesson Extends Partnership With CDC to Fight Coronavirus

by Zacks Equity Research

McKesson (MCK) extends partnership with the CDC to aid in the distribution of future COVID-19 vaccines.

Boston Scientific's Voraxaze's MAA Accepted by EMA for Review

by Zacks Equity Research

Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be upbeat about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes

by Zacks Equity Research

Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.

EPA Validates NEOGEN's Disinfectant for Use Against COVID-19

by Zacks Equity Research

NEOGEN's (NEOG) BioSentry 904 Disinfectant approved by the EPA for use against the COVID-19-causing SARS-CoV-2 virus.

Omnicell, Pharmaceutical Strategies Enter Acquisition Deal

by Zacks Equity Research

Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.

Sweta Killa headshot

5 Top-Ranked Dividend Growth Stocks Still At Bargain Prices

by Sweta Killa

Stocks that have a strong history of dividend growth, as opposed to those that offer high yields, form a healthy portfolio with more scope for capital appreciation.

Here's Why You Should Hold on to Intuitive Surgical Stock Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.

Baxter (BAX) Receives EUA for Regiocit Replacement Solution

by Zacks Equity Research

Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.

Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected (Revised)

by Zacks Equity Research

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.

Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated

by Zacks Equity Research

Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.

Here's Why You Should Hold on to Stryker (SYK) Stock Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.

Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates

by Zacks Equity Research

Accuray (ARAY) registered decline in Product and Service revenues in Q4

Medtronic (MDT) Plans $160 Million R&D Investment in India

by Zacks Equity Research

The newest expansion plan of MEIC will help Medtronic (MDT) advance in the field of pain alleviation and restoration of health.

HMS Holdings (HMSY) Loses 2.9% Since Q2 Earnings Release

by Zacks Equity Research

HMS Holdings (HMSY) witnessed revenue growth in COB segment in Q2.

Medtronic Plans New Acquisition in AI-Driven Diabetes Care

by Zacks Equity Research

Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.

Change Healthcare (CHNG) Gains 1.9% Since Q1 Earnings Beat

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across the Network Solutions segment and lower operating expenses.